CD274 and neoplasm: PD-L1 expression levels in the tumor are associated with a higher likelihood of clinical benefit, which led to the 2019 approval of pembrolizumab as first-line therapy for patients with HNSCC whose tumors have a combined positive score (CPS) of ≥1 [12].